← Leaderboards
Ruijiang Li
Stanford University
$10,760,802
Attributed
$14,417,642
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2012–25$2.5M$1.9M$1.3M$625K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,417,642 · 9
By mechanism
R01$13,383,683 · 7
R00$718,817 · 1
K99$315,142 · 1
Top collaborators
- Maximilian Diehn7 shared
- Billy W Loo5 shared
- Quynh-Thu X Le4 shared
Most similar at Stanford University
Same institution · by research overlap
- Quynh-Thu X Le$15,492,013
- Ameen A. Salahudeen$708,156
- Brian Andrew Hargreaves$16,291,706
- Jia Wu$3,637,726
- Bruce L Daniel$13,717,379
Others in their field
Top investigators on “Image”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$332,241,999
- Leonard Freedman · Leidos Biomedical Research, Inc.$321,574,964
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$217,904,052
- Ethan Schreier · Associated Universities, Inc.$206,468,864
Research focus
ImageImaging BiomarkerTumorEvaluationTreatment ResponseDiagnosisCohortProspectiveValidationTrainingToxic EffectSuccessX-Ray Computed TomographyClinical TranslationBaseData SetHeterogeneityResponseAnatomyStandard CarePhenotypePrognosticMorphologyImproved Outcome
Grant awards (32)
Noninvasive imaging and blood biomarkers for personalized lung cancer immunotherapy$627,344
R01 · FY2025 · CA · contact PI
Precision imaging for risk stratification and personalized therapy of oropharyngeal cancer$604,860
R01 · FY2025 · DE · contact PI
Computational imaging approaches to personalized gastric cancer treatment$575,981
R01 · FY2025 · CA · contact PI
MRI and blood biomarkers of neoadjuvant therapy response and outcomes in rectal cancer$544,093
R01 · FY2025 · CA · contact PI
Noninvasive imaging and blood biomarkers for personalized lung cancer immunotherapy$627,705
R01 · FY2024 · CA · contact PI
Precision imaging for risk stratification and personalized therapy of oropharyngeal cancer$591,021
R01 · FY2024 · DE · contact PI
MRI and blood biomarkers of neoadjuvant therapy response and outcomes in rectal cancer$554,345
R01 · FY2024 · CA · contact PI
Computational imaging approaches to personalized gastric cancer treatment$547,185
R01 · FY2024 · CA · contact PI
Precision imaging for risk stratification and personalized therapy of oropharyngeal cancer$601,493
R01 · FY2023 · DE · contact PI
Computational imaging approaches to personalized gastric cancer treatment$577,660
R01 · FY2023 · CA · contact PI
Imaging and circulating DNA markers to assess early response and predict treatment failure patterns in lung cancer$537,646
R01 · FY2023 · CA · contact PI
Multiregional imaging phenotypes and molecular correlates of aggressive versus indolent breast cancer$438,028
R01 · FY2023 · CA · contact PI
Precision imaging for risk stratification and personalized therapy of oropharyngeal cancer$633,059
R01 · FY2022 · DE · contact PI
Imaging and circulating DNA markers to assess early response and predict treatment failure patterns in lung cancer$537,646
R01 · FY2022 · CA · contact PI
Multiregional imaging phenotypes and molecular correlates of aggressive versus indolent breast cancer$37,460
R01 · FY2022 · CA · contact PI
Imaging and circulating DNA markers to assess early response and predict treatment failure patterns in lung cancer$548,619
R01 · FY2021 · CA · contact PI
Multiregional imaging phenotypes and molecular correlates of aggressive versus indolent breast cancer$485,193
R01 · FY2021 · CA · contact PI
Imaging and circulating DNA markers to assess early response and predict treatment failure patterns in lung cancer$548,619
R01 · FY2020 · CA · contact PI
Multiregional imaging phenotypes and molecular correlates of aggressive versus indolent breast cancer$485,193
R01 · FY2020 · CA · contact PI
MRI-Based Radiation Therapy Treatment Planning$354,198
R01 · FY2020 · CA · contact PI
Imaging and circulating DNA markers to assess early response and predict treatment failure patterns in lung cancer$548,619
R01 · FY2019 · CA · contact PI
Multiregional imaging phenotypes and molecular correlates of aggressive versus indolent breast cancer$470,637
R01 · FY2019 · CA · contact PI
MRI-Based Radiation Therapy Treatment Planning$343,572
R01 · FY2019 · CA · contact PI
Multiregional imaging phenotypes and molecular correlates of aggressive versus indolent breast cancer$487,799
R01 · FY2018 · CA · contact PI
MRI-Based Radiation Therapy Treatment Planning$354,198
R01 · FY2018 · CA · contact PI
MRI-Based Radiation Therapy Treatment Planning$359,444
R01 · FY2017 · CA · contact PI
MRI-Based Radiation Therapy Treatment Planning$362,066
R01 · FY2016 · CA · contact PI
Real-Time Volumetric Imaging for Lung Cancer Radiotherapy$235,054
R00 · FY2016 · CA · contact PI
Real-Time Volumetric Imaging for Lung Cancer Radiotherapy$242,233
R00 · FY2015 · CA · contact PI
Real-Time Volumetric Imaging for Lung Cancer Radiotherapy$241,530
R00 · FY2014 · CA · contact PI
Real-Time Volumetric Imaging for Lung Cancer Radiotherapy$154,521
K99 · FY2013 · CA · contact PI
Real-Time Volumetric Imaging for Lung Cancer Radiotherapy$160,621
K99 · FY2012 · CA · contact PI